{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-026723","form_type":"8-K","ticker":"PLSH","cik":"0001552189","company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","filed_at":"2021-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.998309+00:00","generated_at":"2026-06-28T16:13:06.674869+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Exactus renamed Panacea Life Sciences; 1-for-28 reverse split; Series C-2 preferred issued to cancel 205M shares","bullets":["Company changed name to Panacea Life Sciences Holdings, Inc., effective Oct 25, 2021.","Effected 1-for-28 reverse stock split of common stock.","Designated 100 shares of Series C-2 Convertible Preferred stock, each convertible into 2,050,000 common shares.","Issued all 100 Series C-2 shares to Quintel-MC Inc., owned by CEO Leslie Buttorff, in exchange for canceling 205,000,000 common shares.","CEO Leslie Buttorff is sole owner, officer, and director of Quintel."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-026723","json":"https://secwatch.observer/filing/0001493152-21-026723.json","markdown":"https://secwatch.observer/filing/0001493152-21-026723.md","text":"https://secwatch.observer/filing/0001493152-21-026723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1552189/000149315221026723/0001493152-21-026723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1552189/000149315221026723/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T16:13:06.674869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}